Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice—Potential Link to Cognitive Impairment in Schizophrenia

Molecular Neurobiology

Volumn 54, Issue 3, 2017, Pages 1699-1709

  Chen, Yong ^a   Bang, Sookhee ^a   McMullen, Mary F ^a   Kazi, Hala ^a   Talbot, Konrad ^a   Ho, Mei Xuan ^b   Carlson, Greg ^a   Arnold, Steven E ^a   Ong, Wei Yi ^b   Kim, Sangwon F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antipsychotics; ATP; Cerebral Cortex; Cognition; DHA; Dysbindin; Lipid synthesis; Neurons; NMDA; PUFA; SREBP; Synaptic Plasticity

Indexed keywords

ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; CLOZAPINE; DYSBINDIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SREBF1 PROTEIN, HUMAN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL MEMBRANE DEPOLARIZATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE REPRESSION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; MALE; MEMORY; MICROARRAY ANALYSIS; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCHIZOPHRENIA; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DEFICIENCY; GENE REGULATORY NETWORK; GENETICS; KNOCKOUT MOUSE; LONGITUDINAL STUDY; METABOLISM; ORGAN CULTURE TECHNIQUE; PC12 CELL LINE; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; COGNITIVE DYSFUNCTION; DYSBINDIN; FEMALE; GENE REGULATORY NETWORKS; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; MICE, KNOCKOUT; NEURONS; ORGAN CULTURE TECHNIQUES; PC12 CELLS; RANDOM ALLOCATION; RATS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84957961024     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9773-x     Document Type: Article

References (66)

1. Carlson GC, Talbot K, Halene TB, Gandal MJ, Kazi HA, Schlosser L, Phung QH, Gur RE et al (2011) Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc Natl Acad Sci U S A 108(43):E962–E970
2. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26(4-6):365–384. doi:10.1007/s10571-006-9062-8
3. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11(3):453–456
4. Hattori S, Murotani T, Matsuzaki S, Ishizuka T, Kumamoto N, Takeda M, Tohyama M, Yamatodani A et al (2008) Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 373(2):298–302. doi:10.1016/j.bbrc.2008.06.016
5. Kantrowitz JT, Javitt DC (2010) N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83(3-4):108–121. doi:10.1016/j.brainresbull.2010.04.006
6. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ et al (2004) Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113(9):1353–1363. doi:10.1172/JCI20425
7. Tang J, LeGros RP, Louneva N, Yeh L, Cohen JW, Hahn CG, Blake DJ, Arnold SE et al (2009) Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet 18(20):3851–3863. doi:10.1093/hmg/ddp329
8. Talbot K, Louneva N, Cohen JW, Kazi H, Blake DJ, Arnold SE (2011) Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. PLoS One 6(3):e16886. doi:10.1371/journal.pone.0016886
9. Ghiani CA, Starcevic M, Rodriguez-Fernandez IA, Nazarian R, Cheli VT, Chan LN, Malvar JS, de Vellis J et al (2010) The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth. Mol Psychiatry 15(2):204–215. doi:10.1038/mp.2009.58
10. Dickman DK, Davis GW (2009) The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science 326(5956):1127–1130. doi:10.1126/science.1179685
11. Murotani T, Ishizuka T, Hattori S, Hashimoto R, Matsuzaki S, Yamatodani A (2007) High dopamine turnover in the brains of Sandy mice. Neurosci Lett 421(1):47–51. doi:10.1016/j.neulet.2007.05.019
12. Chen XW, Feng YQ, Hao CJ, Guo XL, He X, Zhou ZY, Guo N, Huang HP et al (2008) DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J Cell Biol 181(5):791–801. doi:10.1083/jcb.200711021
13. Ji Y, Yang F, Papaleo F, Wang HX, Gao WJ, Weinberger DR, Lu B (2009) Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proc Natl Acad Sci U S A 106(46):19593–19598. doi:10.1073/pnas.0904289106
14. Tang TT, Yang F, Chen BS, Lu Y, Ji Y, Roche KW, Lu B (2009) Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression. Proc Natl Acad Sci U S A 106(50):21395–21400. doi:10.1073/pnas.0910499106
15. Cuthbert BN, Insel TR (2013) Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 11:126. doi:10.1186/1741-7015-11-126
16. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P (2010) Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167(7):748–751. doi:10.1176/appi.ajp.2010.09091379
17. Bazan NG (2005) Synaptic signaling by lipids in the life and death of neurons. Mol Neurobiol 31(1-3):219–230
18. Davletov B, Montecucco C (2010) Lipid function at synapses. Curr Opin Neurobiol 20(5):543–549
19. Rohrbough J, Broadie K (2005) Lipid regulation of the synaptic vesicle cycle. Nat Rev Neurosci 6(2):139–150
20. Soldan MM, Pirko I (2012) Biogenesis and significance of central nervous system myelin. Semin Neurol 32(1):9–14
21. Shao W, Espenshade PJ (2012) Expanding roles for SREBP in metabolism. Cell Metab 16(4):414–419. doi:10.1016/j.cmet.2012.09.002
22. Wang X, Sato R, Brown MS, Hua X, Goldstein JL (1994) SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77(1):53–62
23. Espenshade PJ (2006) SREBPs: sterol-regulated transcription factors. J Cell Sci 119(Pt 6):973–976. doi:10.1242/jcs02866
24. Shimano H (2001) Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 40(6):439–452
25. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109(9):1125–1131. doi:10.1172/JCI15593
26. Bramham CR, Worley PF, Moore MJ, Guzowski JF (2008) The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J Neurosci 28(46):11760–11767. doi:10.1523/JNEUROSCI.3864-08.2008
27. Tzingounis AV, Nicoll RA (2006) Arc/Arg3.1: linking gene expression to synaptic plasticity and memory. Neuron 52(3):403–407. doi:10.1016/j.neuron.2006.10.016
28. Bang S, Steenstra C, Kim SF (2012) Striatum specific protein, Rhes regulates AKT pathway. Neurosci Lett 521(2):142–147. doi:10.1016/j.neulet.2012.05.073
29. Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H, Bang S, Choi BR et al (2014) High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis 67:79–87. doi:10.1016/j.nbd.2014.03.011
30. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104(9):3456–3459
31. Arnold SE, Gur RE, Shapiro RM, Fisher KR, Moberg PJ, Gibney MR, Gur RC, Blackwell P et al (1995) Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am J Psychiatry 152(5):731–737
32. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J et al (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12(7):824–828. doi:10.1038/nm1418
33. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR et al (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316–1338. doi:10.1172/JCI59903
34. Benson MA, Sillitoe RV, Blake DJ (2004) Schizophrenia genetics: dysbindin under the microscope. Trends Neurosci 27(9):516–519. doi:10.1016/j.tins.2004.06.004
35. Talbot K (2009) The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. Prog Brain Res 179:87–94. doi:10.1016/s0079-6123(09)17910-4
36. Jeans A, Malins R, Padamsey Z, Reinhart M, Emptage N (2011) Increased expression of dysbindin-1A leads to a selective deficit in NMDA receptor signaling in the hippocampus. Neuropharmacology 61(8):1345–1353. doi:10.1016/j.neuropharm.2011.08.007
37. Karlsgodt KH, Robleto K, Trantham-Davidson H, Jairl C, Cannon TD, Lavin A, Jentsch JD (2011) Reduced dysbindin expression mediates N-methyl-d-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 69(1):28–34. doi:10.1016/j.biopsych.2010.09.012
38. Glen WB Jr, Horowitz B, Carlson GC, Cannon TD, Talbot K, Jentsch JD, Lavin A (2014) Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning. Hippocampus 24(2):204–213. doi:10.1002/hipo.22215
39. Sztainberg Y, Chen A (2010) An environmental enrichment model for mice. Nat Protoc 5(9):1535–1539. doi:10.1038/nprot.2010.114
40. Kondo M, Gray LJ, Pelka GJ, Christodoulou J, Tam PP, Hannan AJ (2008) Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome—Mecp2 gene dosage effects and BDNF expression. Eur J Neurosci 27(12):3342–3350
41. Nag N, Moriuchi JM, Peitzman CG, Ward BC, Kolodny NH, Berger-Sweeney JE (2009) Environmental enrichment alters locomotor behaviour and ventricular volume in Mecp2 1lox mice. Behav Brain Res 196(1):44–48
42. Canfran-Duque A, Casado ME, Pastor O, Sanchez-Wandelmer J, de la Pena G, Lerma M, Mariscal P, Bracher F et al (2013) Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 54(2):310–324. doi:10.1194/jlr.M026948
43. Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, Cussac D (2010) Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedeberg’s Arch Pharmacol 381(5):427–439. doi:10.1007/s00210-010-0499-4
44. Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, Brown AJ (2010) Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J 10(5):396–407
45. Raeder MB, Ferno J, Vik-Mo AO, Steen VM (2006) SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 289(1-2):167–173
46. Steiner J, Martins-de-Souza D, Schiltz K, Sarnyai Z, Westphal S, Isermann B, Dobrowolny H, Turck CW et al (2014) Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. Front Cell Neurosci 8:384. doi:10.3389/fncel.2014.00384
47. Hunt MC, Siponen MI, Alexson SE (2012) The emerging role of acyl-CoA thioesterases and acyltransferases in regulating peroxisomal lipid metabolism. Biochim Biophys Acta 1822(9):1397–1410. doi:10.1016/j.bbadis.2012.03.009
48. Holmsen H, Hindenes JO, Fukami M (1992) Glycerophospholipid metabolism: back to the future. Thromb Res 67(3):313–323
49. Jenkins GM, Frohman MA (2005) Phospholipase D: a lipid centric review. Cell Mol Life Sci 62(19-20):2305–2316. doi:10.1007/s00018-005-5195-z
50. Marcus PI, Talalay P (1956) Induction and purification of alpha- and beta-hydroxysteroid dehydrogenases. J Biol Chem 218(2):661–674
51. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Belanger A (1997) The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62(1):148–158
52. Haller JF, Krawczyk SA, Gostilovitch L, Corkey BE, Zoeller RA (2011) Glucose-6-phosphate isomerase deficiency results in mTOR activation, failed translocation of lipin 1alpha to the nucleus and hypersensitivity to glucose: Implications for the inherited glycolytic disease. Biochim Biophys Acta 1812(11):1393–1402. doi:10.1016/j.bbadis.2011.07.007
53. Okamoto K, Kakuma T, Fukuchi S, Masaki T, Sakata T, Yoshimatsu H (2006) Sterol regulatory element binding protein (SREBP)-1 expression in brain is affected by age but not by hormones or metabolic changes. Brain Res 1081(1):19–27
54. Kim JH, Ong WY (2009) Localization of the transcription factor, sterol regulatory element binding protein-2 (SREBP-2) in the normal rat brain and changes after kainate-induced excitotoxic injury. J Chem Neuroanat 37(2):71–77
55. Ong WY, Hu CY, Soh YP, Lim TM, Pentchev PG, Patel SC (2000) Neuronal localization of sterol regulatory element binding protein-1 in the rodent and primate brain: a light and electron microscopic immunocytochemical study. Neuroscience 97(1):143–153
56. Korb E, Finkbeiner S (2011) Arc in synaptic plasticity: from gene to behavior. Trends Neurosci 34(11):591–598. doi:10.1016/j.tins.2011.08.007
57. Taghibiglou C, Martin HG, Lai TW, Cho T, Prasad S, Kojic L, Lu J, Liu Y et al (2009) Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat Med 15(12):1399–1406
58. Le HS, Muhleisen TW, Djurovic S, Ferno J, Ouriaghi Z, Mattheisen M, Vasilescu C, Raeder MB et al (2010) Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry 15(5):463–472. doi:10.1038/mp.2008.110
59. Le HS, Theisen FM, Haberhausen M, Raeder MB, Ferno J, Gebhardt S, Hinney A, Remschmidt H et al (2009) Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry 14(3):308–317
60. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R et al (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 5(5):298–304. doi:10.1038/sj.tpj.6500323
61. McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK et al (2013) Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One 8(7):e68717. doi:10.1371/journal.pone.0068717
62. Ledesma MD, Martin MG, Dotti CG (2012) Lipid changes in the aged brain: effect on synaptic function and neuronal survival. Prog Lipid Res 51(1):23–35
63. Krugel U (2015) Purinergic receptors in psychiatric disorders. Neuropharmacology. doi:10.1016/j.neuropharm.2015.10.032
64. LaSalle JM, Powell WT, Yasui DH (2013) Epigenetic layers and players underlying neurodevelopment. Trends Neurosci 36(8):460–470. doi:10.1016/j.tins.2013.05.001
65. Spell C, Kolsch H, Lutjohann D, Kerksiek A, Hentschel F, Damian M, von Bergmann K, Rao ML et al (2004) SREBP-1a polymorphism influences the risk of Alzheimer’s disease in carriers of the ApoE4 allele. Dement Geriatr Cogn Disord 18(3-4):245–249
66. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J Neurosci 25(43):9932–9939